Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Pycnogenol, a standardized extract from French maritime pine bark (Pinus pinaster), has been investigated for its potential benefits in peripheral neuropathy, particularly diabetic neuropathy. The evidence supporting its use is limited but does exist in the form of small clinical trials and pilot studies. Several open-label and randomized controlled trials have suggested that Pycnogenol supplementation may reduce symptoms of neuropathy, such as pain, burning, and numbness, especially in patients with diabetes.

For example, a 2006 study published in Angiology found that diabetic patients taking Pycnogenol experienced significant improvements in neuropathic symptoms compared to controls. Another study published in Acta Diabetologica (2008) reported reduced symptoms and improved microcirculation in diabetic patients with neuropathy after Pycnogenol supplementation. The proposed mechanisms include antioxidant effects, improved endothelial function, and microcirculatory support.

However, these studies have limitations: small sample sizes, short durations, and sometimes lack of rigorous methodology. As such, while there is some scientific evidence, it is preliminary and not yet robust enough to recommend Pycnogenol as a standard treatment for peripheral neuropathy. Larger, well-designed trials are needed to confirm efficacy and safety. Overall, the evidence for Pycnogenol in treating peripheral neuropathy is promising but insufficient for strong conclusions.

More about Pycnogenol
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by Pycnogenol

Products containing Pycnogenol